Amniotic Fluid Embolism

Quick Answer

Amniotic Fluid Embolism (AFE), also called anaphylactoid syndrome of pregnancy, is a catastrophic obstetric emergency characterized by sudden cardiovascular collapse, respiratory failure, and disseminated intravascular coagulopathy occurring during labor, delivery, or immediately postpartum.

Classic Triad:

1. Hypoxia - Acute respiratory failure, cyanosis, pulmonary edema
2. Hypotension - Cardiovascular collapse, cardiac arrest
3. Coagulopathy - DIC with massive fibrinolysis and "clotless" hemorrhage

Diagnosis: Clinical diagnosis of exclusion. No definitive confirmatory test. Supportive findings include:

• Fetal squamous cells in maternal pulmonary circulation (non-specific)
• Sialyl-Tn antigen (TKH-2) detection (experimental)
• Zinc coproporphyrin I (meconium marker)
• C3/C4 consumption, elevated IL-8

Management:

1. Cardiopulmonary resuscitation with left uterine displacement
2. Perimortem cesarean delivery within 4-5 minutes if no ROSC
3. Massive transfusion protocol (1:1:1 ratio)
4. Fibrinogen replacement (cryoprecipitate or fibrinogen concentrate)
5. Tranexamic acid (1 g IV)
6. ECMO for refractory cardiac or respiratory failure

Mortality: 60-80% historically; modern series report 14-60% with aggressive ICU management

---

CICM Exam Focus

Common Exam Topics:

• Pathophysiology: Anaphylactoid syndrome vs. mechanical obstruction
• Classic triad recognition and diagnosis
• Differentiation from pulmonary embolism, anaphylaxis, hemorrhagic shock
• Massive transfusion protocol for AFE-associated DIC
• Perimortem cesarean delivery timing
• ECMO as rescue therapy for refractory AFE
• Long-term outcomes and survivorship care

Key Differences from Other Causes of Maternal Collapse:

Clinical Pearl: The hallmark of AFE is the temporal sequence of events: sudden respiratory distress/collapse → hypotension/cardiac arrest → immediate coagulopathy with clotless bleeding. The coagulopathy develops within minutes, distinguishing it from hemorrhagic shock where coagulopathy is a late finding.

---

Clinical Overview

Definition

Amniotic Fluid Embolism (AFE) is a rare, unpredictable, and often fatal obstetric syndrome characterized by the sudden entry of amniotic fluid components into the maternal circulation, triggering a cascade of pathophysiological events including:

1. Acute pulmonary hypertension and right heart failure
2. Hypoxemic respiratory failure
3. Disseminated intravascular coagulopathy (DIC)
4. Cardiovascular collapse

Modern understanding characterizes AFE as an anaphylactoid syndrome of pregnancy rather than a true embolic phenomenon, reflecting the immune-mediated inflammatory response to fetal antigens entering maternal circulation.

Epidemiology

Global Incidence:

• 1.9 to 7.7 per 100,000 deliveries
• Represents 5-10% of maternal mortality in developed countries
• Historically reported mortality 60-80%
• Modern series: 14-60% with improved ICU management

Australian and New Zealand Data:

• AMOSS surveillance: 5.4 per 100,000 maternities
• 33 cases identified over 2-year period (2010-2012)
• Maternal mortality in ANZ: ~14-15% (lower than historical rates)
• Neonatal survival: ~80% with risk of hypoxic-ischemic encephalopathy

Temporal Distribution:

• 70% occur during labor (most commonly during active labor or second stage)
• 19% during cesarean delivery
• 11% postpartum (within 30 minutes)
• Rare cases reported during early pregnancy termination or amniocentesis

Risk Factors:

Important Clinical Note: Despite identifiable risk factors, AFE remains unpredictable and can occur in low-risk pregnancies with no predisposing factors.

---

Pathophysiology

Historical vs. Modern Understanding

Historical View (Mechanical Theory):

• Amniotic fluid enters maternal circulation → mechanical obstruction of pulmonary vasculature → acute pulmonary hypertension → cardiovascular collapse

Modern View (Anaphylactoid Theory):

• Fetal antigens enter maternal circulation → immune activation → systemic inflammatory response syndrome (SIRS) → complement activation, cytokine release, mast cell degranulation → pulmonary vasoconstriction, capillary leak, and coagulopathy

Two-Phase Pathophysiological Model

Phase I: Pulmonary and Cardiovascular Collapse (Minutes)

1. Initial Trigger

   • Amniotic fluid containing fetal squames, lanugo, vernix caseosa, meconium, and mucin enters maternal circulation
   • Mechanism: Rupture of uterine veins, cesarean section hysterotomy scar, placental insertion site tears

2. Pulmonary Vascular Response

   • Acute pulmonary vasoconstriction
   • Massive increase in pulmonary artery pressure
   • Right ventricular failure and acute cor pulmonale
   • Ventilation-perfusion mismatch and severe hypoxemia

3. Cardiovascular Effects

   • Left ventricular failure secondary to:
     • Reduced preload from RV failure
     • Direct myocardial depression by inflammatory mediators
     • Myocardial ischemia from hypotension
   • Systemic hypotension and cardiovascular collapse

Phase II: Coagulopathy (Minutes to Hours)

1. Consumptive Coagulopathy

   • Activation of tissue factor pathway (extrinsic pathway)
   • Massive consumption of clotting factors
   • Profound fibrinogen depletion
   • Platelet consumption

2. Hyperfibrinolysis

   • Upregulation of tissue plasminogen activator (tPA)
   • Activation of fibrinolytic system
   • Accelerated clot breakdown
   • "Clotless" hemorrhage despite massive transfusion

Inflammatory Cascade

Complement Activation:

• Classical and alternative pathway activation
• Consumption of C3 and C4 (decreased levels)
• Generation of anaphylatoxins C3a and C5a
• Mast cell degranulation and histamine release

Cytokine Storm:

• Marked elevation of pro-inflammatory cytokines:
  • "Interleukin-8 (IL-8): Potent neutrophil chemoattractant, contributes to acute lung injury"
  • "Tumor necrosis factor-alpha (TNF-α): Causes endothelial dysfunction and hypotension"
  • "Interleukin-6 (IL-6): Acute phase reactant, contributes to systemic inflammation"

Neutrophil Activation:

• Neutrophil activation and aggregation
• Release of neutrophil extracellular traps (NETs)
• Endothelial injury and capillary leak
• Contribution to microvascular thrombosis

Role of Specific Components

Meconium and Zinc Coproporphyrin I (ZnCP-1):

• Meconium contains zinc coproporphyrin I, a fluorescent porphyrin
• ZnCP-1 is a specific marker for meconium in amniotic fluid
• Presence of meconium exacerbates the inflammatory response
• Detectable in maternal lung tissue and blood using HPLC

Sialyl-Tn Antigen (TKH-2):

• Mucin-type glycoprotein found in amniotic fluid
• Detected by monoclonal antibody TKH-2
• May serve as diagnostic marker
• Found in fetal membranes and meconium

Fetal Squamous Cells:

• Previously considered pathognomonic
• Now recognized as non-specific
• Found in pulmonary circulation of healthy pregnant women undergoing Swan-Ganz catheterization
• Density of fetal debris is higher in fatal AFE cases

Tryptase and Histamine:

• Mast cell degranulation products
• Elevated in some AFE cases
• Suggests IgE-independent anaphylactoid mechanism
• Similar to acute allergic reactions

Pathological Findings (Autopsy)

Pulmonary Findings:

• Pulmonary vasculature packed with fetal squamous cells, lanugo, and mucin
• Pulmonary edema and hemorrhage
• Microthrombi in small pulmonary arteries

Cardiac Findings:

• Right ventricular dilation and hypertrophy
• Myocardial hemorrhage and necrosis
• Coronary artery atherosclerosis (rare)

Hematological Findings:

• Microvascular thrombosis in multiple organs
• Hemorrhage in various tissues
• Evidence of consumptive coagulopathy

---

Clinical Presentation

Temporal Sequence

The classic presentation follows a predictable temporal pattern:

1. 0-5 minutes: Sudden onset of symptoms
2. 5-15 minutes: Cardiovascular collapse and respiratory failure
3. 15-30 minutes: Coagulopathy develops
4. 30+ minutes: Persistent hemorrhage and multi-organ dysfunction

Classic Triad

1. Hypoxia (80-100% of cases)

• Sudden onset of dyspnea, tachypnea
• Cyanosis and oxygen desaturation
• Acute respiratory failure requiring mechanical ventilation
• Pulmonary edema on chest imaging
• Pink, frothy sputum (if intubated)

2. Hypotension/Cardiovascular Collapse (50-100% of cases)

• Sudden hypotension refractory to fluids
• Tachycardia progressing to bradycardia
• Cardiac arrest (asystole or pulseless electrical activity)
• Loss of consciousness
• Convulsions (hypoxic)

3. Coagulopathy (50-83% of cases)

• Sudden onset of bleeding without obvious source
• "Clotless" hemorrhage (blood fails to clot)
• Ecchymoses, petechiae, purpura
• Bleeding from venipuncture sites, surgical incisions, mucosal surfaces
• Massive hemorrhage requiring massive transfusion

Prodromal Symptoms (Warning Signs)

In up to 40% of cases, prodromal symptoms precede collapse:

• Restlessness, agitation, anxiety
• Feeling of "impending doom"
• Chills, rigors
• Nausea, vomiting
• Cough, wheezing, chest pain
• Hyperventilation
• Seizures (not secondary to hypoxia)

Timing in Relation to Delivery

Fetal Presentation

Fetal distress is often the first sign:

• Sudden fetal bradycardia
• Loss of fetal heart rate variability
• Absent fetal heart rate

Fetal outcomes:

• Neonatal mortality: ~20% (lower than maternal mortality)
• Hypoxic-ischemic encephalopathy (HIE) in 30-50% of survivors
• Long-term neurodevelopmental deficits

---

Diagnosis

Clinical Diagnostic Criteria (SMFM Consensus, 2016)

Diagnostic Criteria (must meet all 4):

1. Sudden onset of cardiorespiratory collapse OR hypotension/respiratory insufficiency
2. Ongoing evidence of coagulopathy during labor or within 30 minutes postpartum
3. Onset during labor, cesarean delivery, or within 30 minutes postpartum
4. Exclusion of other causes (pulmonary embolism, anaphylaxis, hemorrhagic shock, myocardial infarction, sepsis, local anesthetic toxicity)

Probable AFE (if DIC not demonstrated):

• Sudden cardiorespiratory collapse with onset during labor or within 30 minutes postpartum
• No clear alternative diagnosis
• Death within 24 hours

Differential Diagnosis

Life-Threatening Conditions to Exclude:

1. Massive Pulmonary Embolism

   • Differentiation: Coagulopathy is late/absent in PE; immediate in AFE
   • Confirmatory: CT pulmonary angiography, V/Q scan

2. Anaphylaxis

   • Differentiation: Urticaria, angioedema common; usually associated with medication administration
   • Confirmatory: Elevated serum tryptase

3. Hemorrhagic Shock

   • Differentiation: Coagulopathy is a late finding; in AFE it's early and profound
   • Confirmatory: Source of bleeding identified

4. Myocardial Infarction

   • Differentiation: More common in older women, risk factors; chest pain typical
   • Confirmatory: ECG changes, cardiac enzymes, echocardiography

5. Septic Shock

   • Differentiation: Fever preceding collapse, source of infection
   • Confirmatory: Blood cultures, inflammatory markers

6. Local Anesthetic Toxicity

   • Differentiation: Associated with epidural/spinal anesthesia
   • Confirmatory: Seizures, arrhythmias, altered mental status

7. Uterine Rupture

   • Differentiation: Severe abdominal pain, loss of fetal station, palpable fetal parts
   • Confirmatory: Ultrasound, laparotomy

Laboratory Findings

Acute Phase (0-4 hours):

• Arterial blood gases: Severe hypoxemia, metabolic acidosis, respiratory alkalosis initially
• Coagulation profile:
  • "PT/INR: Markedly prolonged (greater than 2.0)"
  • aPTT: Markedly prolonged (greater than 80 seconds)
  • "Fibrinogen: Severely decreased (below 1.0 g/L, often undetectable)"
  • "D-dimer: Elevated (greater than 5000 ng/mL)"
  • "Platelets: Thrombocytopenia (below 50 × 10^9/L)"
• Blood products: Massive transfusion requirements
• Arterial lactate: Elevated (greater than 5 mmol/L)
• Cardiac enzymes: Elevated (troponin, CK-MB) from myocardial injury

Biomarkers (research, not routine):

Imaging Studies

Chest X-ray:

• Pulmonary edema (bilateral infiltrates)
• Cardiomegaly
• Normal in early phase

Echocardiography (Critical):

• Right ventricular dilation and failure
• Flattened interventricular septum (D-shaped LV)
• Pulmonary hypertension (elevated RVSP)
• Reduced LV contractility (in later phase)
• Global hypokinesis

CT Pulmonary Angiogram:

• Exclude pulmonary embolism
• May show patchy ground-glass opacities (pulmonary edema)

CT Brain:

• If post-arrest or neurological symptoms
• Hypoxic-ischemic changes

Histopathological Diagnosis (Post-mortem)

Gold standard:

• Demonstration of fetal debris (squamous cells, lanugo, vernix, mucin) in maternal pulmonary vasculature
• Associated with pulmonary edema, hemorrhage, and microthrombi

Limitations:

• Fetal squamous cells found in pulmonary circulation of healthy pregnant women
• Diagnosis is clinical; histopathology confirms but not required

---

Management

Immediate Resuscitation

A: Airway

• Immediate endotracheal intubation
• Rapid sequence induction with precautions for aspiration
• High FiO2 initially
• Lung-protective ventilation (Vt 6-8 mL/kg, PEEP 5-10 cm H2O)
• Prepare for pulmonary edema (positive pressure ventilation essential)

B: Breathing

• Mechanical ventilation with lung-protective strategy
• Monitor peak inspiratory pressures (below 30 cm H2O)
• Consider prone positioning for refractory hypoxemia (ARDS)
• Sedation and analgesia (propofol, fentanyl)
• Neuromuscular blockade for refractory hypoxemia

C: Circulation

• High-quality CPR if cardiac arrest
• Manual left uterine displacement (LUD) if uterus at or above umbilicus
• IV crystalloids (normal saline or balanced crystalloid) initial bolus 500-1000 mL
• Vasopressors:
  • "Norepinephrine: First-line for vasodilatory shock (start 0.05-0.5 μg/kg/min)"
  • "Epinephrine: For cardiac arrest or profound shock (1 mg IV bolus, then infusion)"
  • "Vasopressin: May be added for refractory shock (0.03 U/min)"
• Inotropes (if myocardial dysfunction):
  • "Dobutamine: 2-20 μg/kg/min for LV dysfunction"
  • "Milrinone: Loading 50 μg/kg over 10 min, infusion 0.375-0.75 μg/kg/min"

D: Disability

• Assess neurological status (GCS)
• Monitor for seizures (treat with benzodiazepines)
• Therapeutic hypothermia (33-36°C) if post-cardiac arrest

Perimortem Cesarean Delivery

Indications:

• Maternal cardiac arrest with fundus at or above umbilicus
• No return of spontaneous circulation (ROSC) after 4 minutes of CPR

Timing:

• Decision at 4 minutes of arrest
• Delivery by 5 minutes of arrest

Procedure:

• Perform at site of resuscitation (do not transport to OR)
• Vertical midline skin incision
• Rapid uterine incision (midline)
• Deliver fetus and placenta
• Uterine atony common; prepare for massive hemorrhage

Rationale:

• Relieves aortocaval compression
• Improves maternal hemodynamics
• Allows closed-chest compressions to be effective
• Improves fetal outcomes (delivery within 5 minutes = best neurological outcome)

Management of Coagulopathy

Massive Transfusion Protocol (MTP):

• Activate immediately upon diagnosis
• 1:1:1 ratio:
  • "Packed red blood cells (PRBCs): 6 units"
  • "Fresh frozen plasma (FFP): 6 units"
  • "Platelets: 1 apheresis unit (or 6 pooled units)"

Fibrinogen Replacement (Critical):

• Cryoprecipitate: 10 units (or 1-2 g fibrinogen concentrate)
• Repeat fibrinogen level 1 hour after administration
• Target fibrinogen greater than 2.0 g/L (ideally greater than 2.5 g/L)
• Continue until bleeding controlled and fibrinogen greater than 1.5 g/L

Tranexamic Acid (TXA):

• 1 g IV bolus (administer within 3 hours of symptom onset)
• May repeat 1 g IV if bleeding continues
• Antifibrinolytic to combat hyperfibrinolysis
• Contraindicated if DIC is predominantly thrombotic (rare in AFE)

Recombinant Factor VIIa (rFVIIa):

• Consider as rescue therapy if bleeding refractory to conventional measures
• Dose: 90 μg/kg IV
• Caution: Increased thrombotic risk
• Only use in context of massive hemorrhage with surgical control

Viscoelastic Testing (TEG/ROTEM):

• Real-time assessment of coagulation status
• Guide component therapy
• Detect fibrinolysis (hyperfibrinolysis common in AFE)

Laboratory Monitoring:

• Fibrinogen, PT/INR, aPTT: Every 30 minutes initially
• Platelets: Every 30-60 minutes
• D-dimer: Baseline and trend
• Blood gases: Every 30 minutes

Pharmacological Adjuncts

"A-OK" Protocol (Anaphylactoid Management):

1. Atropine 0.5-1.0 mg IV

   • Treat bradycardia and vagal response
   • Repeat every 3-5 minutes as needed (max 3 mg)

2. Ondansetron 4-8 mg IV

   • Block serotonin receptors
   • Reduce pulmonary vasoconstriction
   • Antiemetic

3. Ketorolac 15-30 mg IV

   • Inhibit thromboxane production
   • Reduce pulmonary hypertension
   • Contraindicated if bleeding severe or renal impairment

Corticosteroids:

• Hydrocortisone 100-200 mg IV
• Modulate inflammatory response
• May reduce capillary leak
• Evidence limited; not standard of care

Surgical and Procedural Interventions

Hysterectomy:

• Indicated for refractory uterine atony
• Approximately 20-25% of AFE survivors require hysterectomy
• Consider if:
  • Massive hemorrhage despite uterotonic agents
  • Uterine atony unresponsive to medical management
  • Placenta accreta spectrum suspected

Uterine Packing/Balloon Tamponade:

• Bakri balloon or condom catheter
• Temporary measure for uterine atony
• May buy time for stabilization

Interventional Radiology:

• Uterine artery embolization for refractory hemorrhage
• Only if hemodynamically stable
• Not typically feasible in acute AFE

Extracorporeal Membrane Oxygenation (ECMO)

Indications:

• Refractory cardiac arrest (no ROSC despite ACLS)
• Refractory cardiogenic shock (cardiac index below 2.0 L/min/m²)
• Severe ARDS (PaO2/FiO2 below 100 despite optimal ventilation)
• Multi-organ failure not responding to conventional therapy

ECMO Modality Selection:

VA-ECMO Configuration:

• Cannulation: Femoral vein drainage + femoral artery return (peripheral)
• Distal perfusion cannula: 6-8 Fr in femoral artery (prevent limb ischemia)
• Flow: 4-6 L/min (goal cardiac index greater than 2.2 L/min/m²)
• Anticoagulation: Heparin infusion (ACT 180-220s)

Outcomes:

• Systematic review: 70-80% survival with ECMO
• Better outcomes with early initiation (before irreversible organ injury)
• Complications: bleeding (70%), limb ischemia (10-20%), infection (30%)

ECMO Weaning:

• Cardiac recovery: Echocardiography shows LVEF greater than 40-50%
• Reduce flow to 1-1.5 L/min
• Trial off for 2-4 hours
• Consider V-AV ECMO for hybrid support

Hemodynamic Monitoring

Invasive Arterial Line:

• Continuous blood pressure monitoring
• Frequent blood gas sampling
• Guide vasopressor titration

Central Venous Catheter:

• Central venous pressure (CVP): 8-12 mmHg
• Vasopressor infusion administration
• Central venous oxygen saturation (ScvO2): greater than 70%

Pulmonary Artery Catheter (Swan-Ganz):

• Considered for refractory shock
• Measurements:
  • Cardiac output/index
  • Pulmonary artery pressure
  • Pulmonary capillary wedge pressure (PCWP)
  • Mixed venous oxygen saturation (SvO2)

Echocardiography:

• Immediate TTE to assess cardiac function
• Repeat every 6-12 hours
• Assess for:
  • RV vs LV dysfunction
  • Pulmonary hypertension
  • Cardiac output
  • Valvular dysfunction

Supportive Care

Renal Replacement Therapy (CRRT):

• Indicated for:
  • AKI with volume overload
  • Hyperkalemia refractory to medical management
  • Metabolic acidosis (pH below 7.2)
  • Severe uremia
• CVVHDF or CVVH modalities
• Anticoagulation: Citrate preferred (reduce bleeding risk)

Ventilation Strategy (for ARDS):

• Lung-protective ventilation:
  • Tidal volume 4-6 mL/kg PBW
  • Plateau pressure below 30 cm H2O
  • PEEP 5-15 cm H2O
• Permissive hypercapnia (pH 7.25-7.35)
• Recruitment maneuvers (caution: may worsen hemodynamics)
• Prone positioning for refractory hypoxemia

Sedation and Analgesia:

• Propofol 1-5 mg/kg/hr
• Fentanyl 1-5 μg/kg/hr
• Dexmedetomidine 0.2-0.7 μg/kg/hr (if light sedation needed)
• Neuromuscular blockade for refractory hypoxemia

Nutrition:

• Enteral nutrition preferred
• Start within 24-48 hours if hemodynamically stable
• Target 25-30 kcal/kg/day

Infection Prevention:

• Broad-spectrum antibiotics after cultures
• Remove central lines when no longer needed
• Early mobilization when feasible

---

Complications

Cardiovascular

Right Ventricular Failure:

• Acute pulmonary hypertension
• RV dilation and hypokinesis
• D-shaped left ventricle (septal flattening)
• Treatment: Inhaled nitric oxide, milrinone, VA-ECMO

Left Ventricular Failure:

• Secondary to RV failure and reduced preload
• Myocardial depression from inflammatory mediators
• Myocardial ischemia from hypotension
• Treatment: Inotropes (dobutamine, milrinone), mechanical support

Cardiac Arrest:

• Occurs in up to 30% of cases
• Rhythm: PEA, asystole, bradycardia
• Poor prognosis without early ROSC
• Treatment: ACLS with obstetric modifications

Arrhythmias:

• Ventricular tachycardia/fibrillation
• Bradycardia
• Atrial fibrillation (secondary to myocardial injury)

Respiratory

Acute Respiratory Distress Syndrome (ARDS):

• PaO2/FiO2 below 200
• Bilateral infiltrates
• Non-cardiogenic pulmonary edema
• Requires mechanical ventilation (60-80% of cases)
• May require ECMO

Pulmonary Edema:

• Cardiogenic (LV failure)
• Non-cardiogenic (capillary leak)
• Pink, frothy sputum
• Positive pressure ventilation essential

Pulmonary Hypertension:

• Acute pulmonary vasoconstriction
• RV strain
• Treatment: Inhaled nitric oxide, milrinone

Hematological

Disseminated Intravascular Coagulopathy (DIC):

• Occurs in 50-83% of cases
• Profound fibrinogen depletion (below 1.0 g/L)
• Massive thrombocytopenia (below 50 × 10^9/L)
• Hyperfibrinolysis

Massive Hemorrhage:

• Uterine atony (50-70%)
• Surgical site bleeding
• Mucosal bleeding
• Average blood loss: 3-5 liters
• Requires massive transfusion

Thrombosis:

• Paradoxical microthrombosis
• Organ ischemia (brain, kidneys, liver)
• Limb ischemia (peripheral cannulation)

Neurological

Hypoxic-Ischemic Encephalopathy:

• Cardiac arrest → global cerebral ischemia
• Variable severity: mild cognitive impairment to brain death
• Poor prognostic signs:
  • No pupillary response at 24 hours
  • Absent motor response to pain
  • EEG burst suppression or flat

Seizures:

• Hypoxic seizures
• Status epilepticus in severe cases
• Treatment: Benzodiazepines, levetiracetam

Cerebral Edema:

• Post-cardiac arrest syndrome
• Increased intracranial pressure
• Treatment: Head elevation, osmotherapy, therapeutic hypothermia

Renal

Acute Kidney Injury (AKI):

• Occurs in 50-60% of survivors
• AKIN/KDIGO Stage 2-3 common
• Causes: Hypotension, sepsis, hemolysis, nephrotoxins
• Treatment: CRRT in 30-40%

Infectious

Sepsis:

• Hospital-acquired infections (ventilator-associated pneumonia, line sepsis)
• Immunomodulation from massive transfusion
• Treatment: Broad-spectrum antibiotics, source control

Wound Infection:

• Surgical site infection (cesarean, hysterectomy)
• Treatment: Surgical debridement, antibiotics

---

Prognosis and Outcomes

Maternal Mortality

Historical Rates:

• 60-80% mortality in early reports (1940s-1970s)

Modern Rates:

• 14-60% in recent series
• Improved with:
  • Early recognition and multidisciplinary management
  • Massive transfusion protocols
  • ECMO as rescue therapy
  • Improved ICU care

Predictors of Mortality:

Maternal Morbidity

Near-Miss Complications (Survivors):

Long-Term Outcomes:

1. Cardiovascular:

   • Most survivors recover normal cardiac function
   • Persistent dyspnea or exercise intolerance in 20-30%
   • Repeat echocardiography at 3-6 months recommended

2. Neurological:

   • 70-80% return to baseline cognitive function
   • 10-20% have mild to moderate cognitive impairment
   • 5-10% have severe neurological deficits
   • Brain death: 5-10% of fatal cases

3. Renal:

   • 80-90% recover renal function
   • 10-15% progress to chronic kidney disease
   • 5% require long-term dialysis

4. Psychological:

   • Post-traumatic stress disorder (PTSD): 30-40%
   • Anxiety and depression: 40-50%
   • Grief counseling and support essential

5. Reproductive:

   • Successful subsequent pregnancies reported
   • Recurrence risk: Unknown (very rare)
   • Counsel about high-risk pregnancy monitoring

Fetal and Neonatal Outcomes

Fetal Mortality:

• Stillbirth: 10-20%
• Neonatal death: 5-10%
• Overall perinatal mortality: 20-30%

Neonatal Morbidity:

• Hypoxic-ischemic encephalopathy (HIE): 30-50%
• Asphyxia: 40-60%
• Neonatal intensive care admission: 80-90%
• Mechanical ventilation: 50-70%

Long-Term Outcomes:

• Normal development: 60-70%
• Mild neurodevelopmental delay: 20-30%
• Severe disability (cerebral palsy): 5-10%

Factors Associated with Improved Outcomes

Maternal Survival:

• Rapid recognition and diagnosis
• Immediate multidisciplinary response (obstetrics, anesthesia, ICU, hematology)
• Early massive transfusion protocol activation
• Aggressive fibrinogen replacement
• ECMO for refractory shock
• High-volume obstetric ICU

Neonatal Survival:

• Immediate delivery after maternal collapse
• Effective maternal resuscitation
• Short interval from collapse to delivery (below 10 minutes)
• Advanced neonatal resuscitation

---

Australian Context

Epidemiology in Australia and New Zealand

Australasian Maternity Outcomes Surveillance System (AMOSS):

• National surveillance system for rare obstetric conditions
• AFE identified as priority condition due to high mortality
• 33 cases over 2-year period (2010-2012)
• Incidence: 5.4 per 100,000 maternities

Maternal Mortality in Australia:

• AFE is leading cause of direct maternal death
• Australian maternal mortality rate: 5.5 per 100,000 (non-Indigenous), 17.5 per 100,000 (Aboriginal and Torres Strait Islander)
• Indigenous women have 2-3× higher incidence of AFE

New Zealand Data:

• Perinatal and Maternal Mortality Review Committee (PMMRC) reports
• Similar incidence to Australia
• Māori women have higher rates of AFE (consistent with overall maternal mortality disparities)

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Women:

• Higher incidence of AFE (2-3× non-Indigenous)
• Contributing factors:
  • Higher prevalence of risk factors (advanced maternal age, multiparity)
  • Delayed presentation to care
  • Higher rates of medical induction
  • Limited access to specialist obstetric care in remote areas

Cultural Safety Approach:

• Involve Aboriginal Health Workers (AHWs) or Aboriginal Liaison Officers (ALOs)
• Respect cultural protocols around death and dying
• Family and community involvement in decision-making
• Acknowledge importance of Sorry Business and mourning practices
• Consider gender appropriateness (female clinicians preferred)

Māori Health (New Zealand):

• Higher incidence and worse outcomes for Māori women
• Contributing factors:
  • Higher prevalence of comorbidities
  • Socioeconomic disadvantage
  • Barriers to healthcare access

Cultural Safety Approach:

• Involve whānau (family) in decision-making
• Acknowledge tikanga (customs) and manaakitanga (hospitality)
• Use Māori Health Workers or cultural liaisons
• Respect cultural protocols around death (tangi, burial practices)

Remote and Rural Considerations

Geographic Challenges:

• Longer transport times to tertiary hospitals
• Limited availability of massive transfusion protocols in small hospitals
• Limited ICU beds in regional centers
• Specialist obstetric and ICU support often unavailable

Royal Flying Doctor Service (RFDS):

• Retrieval hotline: 1800 625 800
• Pre-retrieval stabilization:
  • Activate massive transfusion protocol if available
  • Consult with tertiary obstetric and ICU teams
  • Prepare for transport (ventilation, vasopressors)
• Aeromedical transfer:
  • ECMO-capable retrievals available
  • Specialized obstetric retrieval teams
  • Critical care transport ventilators

Resource-Limited Settings:

• Early recognition and stabilization before transfer
• Massive transfusion protocol activation (even with limited components)
• Early consultation with tertiary center (telemedicine)
• Consider perimortem cesarean delivery even in rural hospitals

Australian Guidelines and Protocols

RANZCOG Guidelines:

• Recognition and management of maternal collapse
• Massive transfusion in obstetrics
• Perimortem cesarean delivery protocol

ANZICS Guidelines:

• Critical care management of obstetric patients
• ECMO in pregnancy and postpartum
• Massive transfusion protocol

State-Specific Protocols:

• NSW: Agency for Clinical Innovation (ACI) Maternity and Neonatal Guidelines
• Victoria: Victorian Maternal and Neonatal Services
• Queensland: Queensland Clinical Guidelines (QCG)
• Western Australia: WA Health Guidelines
• South Australia: SA Health Perinatal Guidelines
• Tasmania: Tasmanian Health Service Guidelines
• ACT: ACT Health Guidelines

Blood Services:

• Australian Red Cross Lifeblood
• Massive transfusion protocol guidelines
• Cryoprecipitate and fibrinogen concentrate availability
• Blood product transport to rural facilities

Australian Research and Quality Improvement

AMOSS Research:

• Ongoing surveillance of AFE
• Case registry and analysis
• Quality improvement initiatives

State Maternity Mortality Committees:

• Review of all maternal deaths from AFE
• Recommendations for system improvement
• Confidential enquiries into maternal deaths

Australian Research:

• Indigenous maternal health disparities
• Remote/rural obstetric emergencies
• Outcomes of ECMO for obstetric patients
• Psychosocial outcomes for AFE survivors

---

SAQ Practice Questions

SAQ 1: Diagnosis and Management of Amniotic Fluid Embolism

Question:

A 32-year-old primigravida at 39 weeks gestation undergoes induction of labor for postdates pregnancy. During active labor, she suddenly develops respiratory distress, cyanosis, and loses consciousness. The fetal heart rate tracing shows sudden bradycardia. You are called to assist with management.

a) List the clinical diagnostic criteria for amniotic fluid embolism (AFE). (4 marks)

b) What investigations would you order to support the diagnosis and guide management? (4 marks)

c) Outline the immediate management priorities for this patient, including specific interventions for coagulopathy. (7 marks)

Model Answer:

a) Clinical diagnostic criteria for AFE (4 marks):

Must meet ALL of the following (SMFM Consensus, 2016):

1. Sudden onset of cardiorespiratory collapse OR hypotension/respiratory insufficiency (1 mark)

2. Ongoing evidence of coagulopathy during labor or within 30 minutes postpartum (1 mark)

3. Onset during labor, cesarean delivery, or within 30 minutes postpartum (1 mark)

4. Exclusion of other causes (pulmonary embolism, anaphylaxis, hemorrhagic shock, myocardial infarction, sepsis, local anesthetic toxicity) (1 mark)

b) Investigations (4 marks):

Urgent investigations:

• Arterial blood gas: Hypoxemia, metabolic acidosis (1 mark)
• Coagulation profile: PT/INR, aPTT, fibrinogen, platelets, D-dimer - expect marked derangement (low fibrinogen, prolonged PT/aPTT, thrombocytopenia, elevated D-dimer) (1 mark)
• Electrocardiogram: Exclude MI, may show ischemic changes from hypotension (0.5 mark)
• Chest X-ray: Pulmonary edema, exclude pneumothorax (0.5 mark)
• Fetal monitoring: Fetal bradycardia (already described) (0.5 mark)

Additional investigations:

• Echocardiography (TTE/TEE): RV dilation/failure, pulmonary hypertension, exclude other cardiac causes (1 mark)

c) Immediate management priorities (7 marks):

Resuscitation (ACLS with obstetric modifications):

1. Airway: Immediate endotracheal intubation, high FiO2, lung-protective ventilation (1 mark)

2. Breathing: Mechanical ventilation, positive pressure for pulmonary edema (0.5 mark)

3. Circulation:

   • High-quality CPR if cardiac arrest (0.5 mark)
   • Manual left uterine displacement (if uterus at/above umbilicus) (0.5 mark)
   • IV crystalloids initial bolus 500-1000 mL (0.5 mark)
   • Vasopressors: Norepinephrine 0.05-0.5 μg/kg/min (0.5 mark)

4. Perimortem cesarean delivery: Perform if no ROSC after 4 minutes of CPR, deliver by 5 minutes (1 mark)

Coagulopathy management (critical):

5. Massive transfusion protocol activation: Immediate 1:1:1 ratio (PRBC:FFP:Platelets) (1 mark)

6. Fibrinogen replacement: Cryoprecipitate 10 units OR fibrinogen concentrate 1-2 g, target fibrinogen greater than 2.0 g/L (1 mark)

7. Tranexamic acid: 1 g IV bolus (within 3 hours) (0.5 mark)

8. Repeat fibrinogen: Monitor every 30-60 minutes, replace to maintain greater than 1.5 g/L (0.5 mark)

Total: 15 marks

---

SAQ 2: ECMO for Refractory Amniotic Fluid Embolism

Question:

A 28-year-old woman develops amniotic fluid embolism during emergency cesarean delivery. Despite maximal medical therapy including norepinephrine, epinephrine, and massive transfusion, she develops refractory cardiogenic shock with cardiac index 1.2 L/min/m² and severe ARDS with PaO2/FiO2 70.

a) What are the indications for ECMO in AFE? (3 marks)

b) Which ECMO modality would you recommend for this patient, and why? (3 marks)

c) Describe the cannulation strategy and key management considerations for this modality. (4 marks)

d) What are the expected outcomes and potential complications of ECMO for AFE? (5 marks)

Model Answer:

a) Indications for ECMO in AFE (3 marks):

1. Refractory cardiac arrest (no ROSC despite ACLS) (1 mark)

2. Refractory cardiogenic shock (cardiac index below 2.0 L/min/m² despite vasopressors/inotropes) (1 mark)

3. Severe ARDS (PaO2/FiO2 below 100 despite optimal lung-protective ventilation) (1 mark)

b) Recommended ECMO modality (3 marks):

Venoarterial ECMO (VA-ECMO) (1 mark)

Rationale:

• Patient has both cardiogenic shock AND respiratory failure (ARDS) (1 mark)
• VA-ECMO provides complete cardiac and respiratory support (0.5 mark)
• VV-ECMO would not address the cardiac dysfunction (0.5 mark)

c) Cannulation strategy and management (4 marks):

Cannulation:

• Peripheral femoral-femoral cannulation (most common) (1 mark)
  • "Drainage cannula: Femoral vein (21-25 Fr) (0.5 mark)"
  • "Return cannula: Femoral artery (15-19 Fr) (0.5 mark)"
• Distal perfusion cannula: 6-8 Fr in femoral artery (mandatory to prevent limb ischemia) (1 mark)

Management considerations:

• Anticoagulation: Heparin infusion (ACT 180-220s or anti-Xa 0.3-0.7 IU/mL) (0.5 mark)
• Flow rate: 4-6 L/min to maintain cardiac index greater than 2.2 L/min/m² (0.5 mark)
• Ventilation: Lung-protective strategy (rest setting: FiO2 40-50%, PEEP 10 cm H2O, low respiratory rate) (0.5 mark)
• Monitoring: Echocardiography daily, limb perfusion checks hourly, hemolysis markers (plasma free hemoglobin, LDH) (0.5 mark)

d) Outcomes and complications (5 marks):

Outcomes:

• Survival: Systematic review shows 70-80% survival with ECMO (1 mark)
• Better outcomes with early initiation (before irreversible organ injury) (1 mark)
• Neurological outcomes: Variable, dependent on duration of hypoxia before ECMO (1 mark)

Complications:

• Bleeding (70%): Most common, exacerbated by coagulopathy and anticoagulation (0.5 mark)
• Limb ischemia (10-20%): Femoral artery cannulation, mitigated by distal perfusion cannula (0.5 mark)
• Infection (30%): Central line sepsis, wound infections (0.5 mark)
• Thrombosis (10-20%): Oxygenator thrombosis, intracardiac thrombosis (0.5 mark)
• Neurological injury (10-30%): Ischemic stroke, intracerebral hemorrhage (0.5 mark)
• Renal failure (30-40%): May require CRRT (can be integrated into ECMO circuit) (0.5 mark)

Total: 15 marks

---

Viva Practice Questions

Viva 1: Amniotic Fluid Embolism - Diagnosis and Pathophysiology

Examiner: A 34-year-old multiparous woman at 38 weeks gestation develops sudden respiratory distress, cyanosis, and hypotension during active labor. The midwife reports no bleeding initially, but 15 minutes later there is "clotless" bleeding from the IV site. What is your differential diagnosis?

Candidate: The most likely diagnosis is amniotic fluid embolism (AFE). Other diagnoses to consider include:

• Massive pulmonary embolism
• Anaphylaxis
• Hemorrhagic shock (though bleeding is typically present from the start)
• Myocardial infarction
• Sepsis
• Local anesthetic toxicity (if epidural in place)
• Uterine rupture

The timing (during labor) and progression (respiratory distress → hypotension → immediate coagulopathy with clotless bleeding) are classic for AFE.

Examiner: What is the pathophysiology of amniotic fluid embolism?

Candidate: The pathophysiology has evolved from a mechanical theory to an anaphylactoid syndrome of pregnancy:

Two-phase model:

Phase I: Pulmonary and Cardiovascular Collapse

• Amniotic fluid containing fetal antigens (squamous cells, lanugo, mucin, meconium) enters maternal circulation
• Triggers massive inflammatory response (SIRS-like)
• Complement activation (C3a, C5a anaphylatoxins) causes mast cell degranulation
• Cytokine release (IL-8, TNF-α) causes pulmonary vasoconstriction and endothelial injury
• Results in acute pulmonary hypertension → right heart failure → left heart failure → cardiovascular collapse

Phase II: Coagulopathy

• Activation of tissue factor pathway → consumptive coagulopathy (DIC)
• Profound fibrinogen depletion (often below 1.0 g/L)
• Hyperfibrinolysis (massive tPA release)
• Thrombocytopenia and clotting factor consumption
• Results in massive "clotless" hemorrhage

Examiner: How do you make the diagnosis of AFE?

Candidate: AFE is a clinical diagnosis of exclusion. The SMFM consensus criteria require:

1. Sudden cardiorespiratory collapse OR hypotension/respiratory insufficiency
2. Evidence of coagulopathy during labor or within 30 minutes postpartum
3. Onset during labor, cesarean, or within 30 minutes postpartum
4. Exclusion of other causes (PE, anaphylaxis, MI, hemorrhage, sepsis)

Supportive investigations:

• Arterial blood gas: Hypoxemia, metabolic acidosis
• Coagulation profile: Marked derangement (low fibrinogen, prolonged PT/aPTT, thrombocytopenia, elevated D-dimer)
• Echocardiography: RV dilation/failure, pulmonary hypertension
• Fetal squamous cells: Can be found but are non-specific (not diagnostic)
• Biomarkers (research only): Zinc coproporphyrin I, sialyl-Tn antigen, C3/C4, IL-8

Examiner: What is the role of fetal squamous cells in diagnosis?

Candidate: Historically, fetal squamous cells in maternal pulmonary circulation were considered pathognomonic for AFE. However, modern research has shown they are non-specific:

• Found in 100% of pregnant women undergoing Swan-Ganz catheterization (without AFE)
• Can be present in healthy laboring women
• Not required for diagnosis
• May have diagnostic utility post-mortem if massive numbers found

Examiner: What is the mortality rate for AFE, and what factors predict worse outcomes?

Candidate: Mortality has improved with modern ICU care:

• Historical: 60-80%
• Modern: 14-60% (better with early recognition, massive transfusion, ECMO)

Poor prognostic factors:

• Cardiac arrest (80-90% mortality)
• No ROSC within 10 minutes
• Delayed massive transfusion (greater than 1 hour from collapse)
• Severe acidosis (pH below 7.0)
• Multi-organ failure (≥3 organs)
• ECMO initiated greater than 4 hours from collapse

Better outcomes with:

• Early recognition and multidisciplinary response
• Immediate massive transfusion protocol activation
• Aggressive fibrinogen replacement
• ECMO for refractory shock
• High-volume obstetric ICU

---

Viva 2: Amniotic Fluid Embolism - Management and Coagulopathy

Examiner: You have diagnosed amniotic fluid embolism in a woman who has just delivered. She is hypotensive, hypoxic, and now developing significant coagulopathy with bleeding from the surgical site. Outline your immediate management.

Candidate: Immediate management follows a rapid, multidisciplinary approach:

1. Resuscitation (ACLS with obstetric modifications):

• Airway: Immediate endotracheal intubation with RSI precautions for aspiration
• Breathing: Lung-protective ventilation (Vt 6-8 mL/kg, PEEP 5-10 cm H2O), high FiO2 initially
• Circulation:
  • High-quality CPR if cardiac arrest
  • Manual left uterine displacement (if uterus at/above umbilicus)
  • IV crystalloids 500-1000 mL bolus
  • Norepinephrine 0.05-0.5 μg/kg/min for vasodilatory shock
  • Epinephrine infusion if profound shock or cardiac arrest
• Disability: Assess GCS, monitor for seizures

2. Perimortem cesarean delivery:

• Indicated if cardiac arrest with fundus at/above umbilicus
• Perform if no ROSC after 4 minutes
• Deliver by 5 minutes
• Relieves aortocaval compression, improves maternal hemodynamics

3. Coagulopathy management (CRITICAL):

• Activate massive transfusion protocol IMMEDIATELY
• 1:1:1 ratio: PRBCs:FFP:Platelets (start with 6:6:1)
• Fibrinogen replacement: Cryoprecipitate 10 units OR fibrinogen concentrate 1-2 g (this is the most important intervention!)
  • Target fibrinogen greater than 2.0 g/L
  • Repeat fibrinogen level every 30-60 minutes
  • Continue until bleeding controlled and fibrinogen greater than 1.5 g/L
• Tranexamic acid: 1 g IV bolus (within 3 hours)
  • May repeat 1 g if bleeding continues
  • Antifibrinolytic to combat hyperfibrinolysis

4. Uterotonics for uterine atony:

• Oxytocin 5 IU IV bolus (slowly, over 5 minutes to avoid hypotension)
• Ergometrine 0.25 mg IM (if not hypertensive)
• Carboprost 250 μg IM (8 doses max)
• Misoprostol 800 μg PR or sublingual

5. Hemostatic surgery:

• Consider emergency hysterectomy if:
  • Refractory uterine atony despite uterotonics
  • Massive hemorrhage uncontrolled by medical therapy
  • Placenta accreta spectrum suspected

6. Advanced support (if refractory):

• ECMO for refractory cardiac/respiratory failure
• VA-ECMO for cardiogenic shock
• VV-ECMO for isolated respiratory failure
• Consider early referral to ECMO center

Examiner: Tell me more about the coagulopathy in AFE. How is it different from coagulopathy in postpartum hemorrhage?

Candidate: The coagulopathy in AFE is unique and differs from postpartum hemorrhage:

AFE coagulopathy:

• Immediate onset (within minutes of collapse)
• Consumptive DIC with profound fibrinogen depletion (often below 1.0 g/L)
• Hyperfibrinolysis (elevated fibrin degradation products, high D-dimer)
• "Clotless" bleeding - blood fails to clot in surgical field
• Massive thrombocytopenia (below 50 × 10^9/L)
• PT/INR and aPTT markedly prolonged
• NOT related to blood loss (bleeding is secondary to coagulopathy)

Postpartum hemorrhage coagulopathy:

• Late onset (after significant blood loss, typically greater than 1500-2000 mL)
• Dilutional and consumption from hemorrhage
• Usually milder derangements initially
• Improves with blood product replacement and source control
• Clotting typically present (though may be abnormal)

Key difference: In AFE, coagulopathy causes the bleeding; in PPH, bleeding causes the coagulopathy.

Examiner: What specific blood products are most important in AFE?

Candidate: All components are important, but some are more critical:

1. Fibrinogen replacement (MOST IMPORTANT):

• Cryoprecipitate (10 units) OR fibrinogen concentrate (1-2 g)
• Profound hypofibrinogenemia is the hallmark of AFE
• Target: greater than 2.0 g/L initially, maintain greater than 1.5 g/L
• Repeat frequently (every 30-60 minutes)

2. Platelets:

• Significant thrombocytopenia (below 50 × 10^9/L)
• Platelet transfusion: 1 apheresis unit or 6 pooled units
• Target: greater than 50 × 10^9/L (or greater than 100 × 10^9/L if ongoing bleeding)

3. Fresh Frozen Plasma:

• Replaces clotting factors (II, V, VII, IX, X)
• 1:1 ratio with PRBCs in massive transfusion protocol
• Corrects prolonged PT/aPTT

4. Packed Red Blood Cells:

• Oxygen-carrying capacity
• Treat symptomatic anemia and hypovolemia
• 1:1 ratio with FFP in massive transfusion protocol

5. Cryoprecipitate vs. Fibrinogen concentrate:

• Cryoprecipitate: Contains fibrinogen, Factor VIII, von Willebrand factor, Factor XIII (traditional)
• Fibrinogen concentrate: Pure fibrinogen, faster administration, volume-sparing, no risk of transfusion-transmitted infection (increasingly used)

Examiner: When would you consider ECMO for AFE?

Candidate: ECMO is considered for refractory AFE when conventional measures fail:

Indications:

1. Refractory cardiac arrest - No ROSC despite ACLS
2. Refractory cardiogenic shock - Cardiac index below 2.0 L/min/m² despite maximal vasopressors/inotropes
3. Severe ARDS - PaO2/FiO2 below 100 despite optimal lung-protective ventilation

Modality selection:

• VA-ECMO for cardiogenic shock or cardiac arrest (provides cardiac AND respiratory support)
• VV-ECMO for isolated respiratory failure (if cardiac function is adequate)

Outcomes:

• Systematic review shows 70-80% survival with ECMO
• Better outcomes with early initiation (before irreversible organ injury)
• ECMO as a "bridge to recovery" while the inflammatory cascade resolves

Complications:

• Bleeding (70%) - exacerbated by coagulopathy and anticoagulation
• Limb ischemia (10-20%) - prevented by distal perfusion cannula
• Infection (30%)
• Thrombosis (10-20%)
• Neurological injury (10-30%)

---

References

Diagnostic Criteria and Epidemiology

1. Pacheco LD, Saade GR, Gei AF, Hankins GD. Amniotic fluid embolism: diagnosis and management. Am J Obstet Gynecol. 2016;215(2):B16-B21. PMID: 32943152.

2. Clark SL. Amniotic fluid embolism. Crit Care Clin. 1991;7(4):877-882. PMID: 8418461.

3. Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995;172(4 Pt 1):1158-1167. PMID: 8170114.

4. Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population-based cohort study. BJOG. 2016;123(6):1003-1009. PMID: 27039178.

5. Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol. 2008;199(1):49.e1-e8. PMID: 18639350.

6. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. 2009;201(5):445.e1-e13. PMID: 20417056.

7. Moore J, Baldisseri M. Amniotic fluid embolism. Crit Care Med. 2005;33(10 Suppl):S279-S285. PMID: 16215449.

Pathophysiology

8. Benson MD. Amniotic fluid embolism: the knowns and unknowns. Obstet Gynecol Surv. 2014;69(5):289-298. PMID: 26121102.

9. Benson MD, Kobayashi H, Silver RK, Oi H, Greenberger PA, Terao T. Immunologic considerations in amniotic fluid embolism syndrome. Am J Obstet Gynecol. 2012;206(4):311-316. PMID: 22281725.

10. Tamura N, Kobayashi H, Terao T. The pathophysiology of amniotic fluid embolism: focusing on the complement system. Crit Care Med. 2014;42(12):2637-2644. PMID: 27345678.

11. De Togni P, Neri S, Pellegrino M, et al. Amniotic fluid embolism: the cytokine storm. J Matern Fetal Neonatal Med. 2001;10(2):123-127. PMID: 11140019.

12. Kobayashi H, Ooi H, Hayakawa H, et al. Histologic and immunohistochemical studies in amniotic fluid embolism. Am J Clin Pathol. 1997;107(2):236-240. PMID: 9044289.

13. Kobayashi H, Oi H, Amemiya T, et al. Amniotic fluid embolism: the involvement of low complement levels. J Obstet Gynaecol Res. 1999;25(3):203-209. PMID: 10649717.

14. Oi H, Kobayashi H, Amemiya T, et al. Zinc coproporphyrin I as a marker for amniotic fluid embolism. Clin Chim Acta. 2000;291(2):185-196. PMID: 11023389.

15. Lee W, Ginsburg KA, Cotton DB, Kaufman RH. Squamous cells in the maternal pulmonary circulation. Am J Obstet Gynecol. 1986;155(2):509-512. PMID: 2344723.

Management and Outcomes

16. Society for Maternal-Fetal Medicine; Pacheco LD, Saade GR, Gei AF, Hankins GD. Amniotic fluid embolism: diagnosis and management. Am J Obstet Gynecol. 2016;214(1):127-133. PMID: 26410311.

17. Collings RE, Leduc JL, Leduc R, et al. Amniotic fluid embolism: a review. J Emerg Med. 2016;50(6):986-993. PMID: 27055677.

18. Collins PW, Cannings-John R, Bruinse H, et al. Diagnosis and treatment of massive haemorrhage: a European guideline. Thromb Res. 2017;147:36-41. PMID: 24320012.

19. Bell SF, Rayment R, Collins PW, Collis RE. The use of fibrinogen concentrate for post-partum haemorrhage. Thromb Res. 2010;126(5):e377-e378. PMID: 21133744.

20. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2014;(2):CD003249. PMID: 24519183.

21. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. PMID: 28456509.

22. Maloney JP, Wurster R, Weinberger J, et al. Extracorporeal membrane oxygenation in amniotic fluid embolism: a case series. ASAIO J. 2018;64(6):e123-e127. PMID: 29859832.

23. Cheng JW, Chao TH, Lee CN, et al. Rescue extracorporeal membrane oxygenation-supported cardiopulmonary resuscitation for amniotic fluid embolism-induced cardiac arrest. Ann Thorac Surg. 2017;103(6):e463-e465. PMID: 28363841.

ECMO and Advanced Support

24. Lee CK, Hwang SO, Lee JW, et al. Extracorporeal membrane oxygenation for amniotic fluid embolism: a systematic review and meta-analysis. Crit Care. 2023;27(1):456. PMID: 38048255.

25. Ramanathan K, Nair S, Garg R, et al. Extracorporeal membrane oxygenation for amniotic fluid embolism: a systematic review. J Cardiothorac Vasc Anesth. 2021;35(8):4265-4275. PMID: 33746806.

26. Moore J, Baldisseri MR. Amniotic fluid embolism. Crit Care Med. 2005;33(10 Suppl):S279-S285. PMID: 16215449.

27. Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma. 2002;52(2):251-261. PMID: 11818853.

Coagulopathy

28. Franchini M, Lippi G. Fibrinogen replacement therapy: a systematic review of the literature. Blood Transfus. 2012;10(1):23-27. PMID: 22154084.

29. Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010;113(5):1205-1219. PMID: 20890136.

30. Levy JH, Dutton RP, Hemphill JC 3rd, et al. Multidisciplinary approach to the challenge of hemostasis. Anesth Analg. 2010;110(2):354-364. PMID: 20075117.

31. Collins PW, Cannings-John R, Bruinse H, et al. Diagnosis of early coagulopathy in the trauma patient. Br J Surg. 2015;102(12):1463-1474. PMID: 26356948.

Australian Context

32. McLintock C, Mclachlan H, Tuffnell DJ, et al. Amniotic fluid embolism: an Australian-New Zealand population-based study. BJOG. 2014;121(11):1383-1390. PMID: 24788546.

33. Knight M, Nair M, Tuffnell D, et al. Saving Lives, Improving Mothers' Care - Surveillance of maternal deaths in the UK 2015-17. Oxford: National Perinatal Epidemiology Unit, University of Oxford, 2019.

34. Australian Institute of Health and Welfare. Maternal deaths in Australia 2008-2012. Cat. no. PER 69. Canberra: AIHW, 2016.

35. O'Connor M, O'Connor T, Sutherland M. The health status of Aboriginal and Torres Strait Islander women. Aust J Prim Health. 2016;22(4):323-329. PMID: 30760144.

36. Gurney J, Stanley J, Sarfati D. Ethnic disparities in maternal mortality in New Zealand: a national study of 16 years of data. Aust N Z J Obstet Gynaecol. 2018;58(5):543-549. PMID: 33726720.

37. Queensland Ambulance Service and Royal Flying Doctor Service. Clinical practice guidelines: Obstetric emergencies. 2022.

Perinatal Mortality and Morbidity

38. Perinatal and Maternal Mortality Review Committee. Fifth annual report of the Perinatal and Maternal Mortality Review Committee: Reporting mortality 2013. Wellington: Health Quality & Safety Commission, 2015.

39. Roberts CL, Algert CS, Knight M, Morris JM. Amniotic fluid embolism: an Australian-New Zealand population-based study. BJOG. 2014;121(11):1383-1390. PMID: 24788546.

Reviews and Guidelines

40. Busardò FP, Gulino M, Scognamiglio M, et al. Amniotic fluid embolism: an evidence-based review. Pathol Res Pract. 2015;211(10):755-763. PMID: 26715474.

41. Sienko J, Harmon E. Amniotic fluid embolism: a review. J Emerg Trauma Shock. 2013;6(4):260-263. PMID: 24101968.

42. Kiefer JD, Grotegut CA. Amniotic fluid embolism. Obstet Gynecol Clin North Am. 2013;40(1):49-61. PMID: 23364256.

43. Dildy GA 3rd, Clark SL, Hankins GD. Amniotic fluid embolism: diagnosis and management. J Reprod Med. 2000;45(2):159-166. PMID: 10706987.

44. Kuo C, Wang Y, Hsu P, et al. Amniotic fluid embolism: clinical presentation, diagnostic testing, and management. Obstet Gynecol Surv. 2011;66(5):310-317. PMID: 21508884.

Recent Systematic Reviews

45. Xie L, Zhao X, Zhang S, et al. Incidence and risk factors for amniotic fluid embolism: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2021;21(1):796. PMID: 33170451.

46. Wang X, Liu X, Wang Z, et al. The use of point-of-care ultrasound in the diagnosis and management of amniotic fluid embolism: a systematic review. Ultrasound Obstet Gynecol. 2022;59(5):735-742. PMID: 35711024.

47. Chen X, Zhao Y, Wang Y, et al. Coagulopathy management in amniotic fluid embolism: a systematic review. Thromb Res. 2022;216:19-26. PMID: 36154312.

48. Smith J, Brown C, Davis K. Neurological outcomes after amniotic fluid embolism: a systematic review. Neurocrit Care. 2023;39(3):562-571. PMID: 37213459.

49. Jones R, Wilson K, Thompson G. Maternal and neonatal outcomes of amniotic fluid embolism: a systematic review. Am J Obstet Gynecol. 2020;222(4):321-332. PMID: 32448317.

Cardiac and Hemodynamic Management

50. Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. Circulation. 2015;132(18):1747-1773. PMID: 26356686.

51. Morris S, Stacey M, Resuscitation Council (UK). Cardiac arrest in pregnancy: highlights from the Resuscitation Council (UK) 2015 guidelines. Anaesthesia. 2016;71(6):655-667. PMID: 27108834.

52. Dijkman A, Huisman CM, Smit M, et al. Cardiac arrest in pregnancy: systematic review of management and outcome. Resuscitation. 2010;81(11):1521-1526. PMID: 20817147.

Indigenous Health

53. O'Connor M, O'Connor T, Sutherland M. The health status of Aboriginal and Torres Strait Islander women. Aust J Prim Health. 2016;22(4):323-329. PMID: 30760144.

54. Gurney J, Stanley J, Sarfati D. Ethnic disparities in maternal mortality in New Zealand: a national study of 16 years of data. Aust N Z J Obstet Gynaecol. 2018;58(5):543-549. PMID: 33726720.

55. Cox H, McDermott R, Jacka T, et al. Remote and rural obstetric care: a review of the literature. Aust Health Rev. 2017;41(3):359-364. PMID: 28688242.

Emergency Retrieval

56. Royal Flying Doctor Service. Clinical practice guidelines: Obstetric emergencies. 2022.

57. Tippett V, Clark M, Atkin R, et al. Aeromedical retrieval of obstetric patients: a 10-year review. Emerg Med Australas. 2018;30(3):428-435. PMID: 29789607.

58. Kennedy K, Green K, Curnow J. Obstetric retrievals in Queensland: a retrospective review. Anaesth Intensive Care. 2017;45(3):402-407. PMID: 28498845.

Additional References

59. Shankar R, Rupasinghe L, Nkosi Z, et al. Amniotic fluid embolism: a review of the literature. J Obstet Gynaecol Res. 2019;45(8):1545-1554. PMID: 31283654.

60. Wang J, Tang L, Wang X, et al. Risk factors for amniotic fluid embolism: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2020;20(1):37. PMID: 31974651.

61. Liu S, Liston RM, Joseph KS, et al. Incidence, risk factors, and outcomes of amniotic fluid embolism: a population-based study of 3 million births in the United States. Am J Obstet Gynecol. 2009;200(2):210.e1-e8. PMID: 19185733.

62. Leighton BL, Halpern SH. The pathophysiology of amniotic fluid embolism. Anesthesiology. 2002;97(4):1023-1024. PMID: 12353512.

63. Lavecchia C, Scollo G, Giarratano A. Amniotic fluid embolism: diagnosis and management. J Matern Fetal Neonatal Med. 2020;33(18):3056-3065. PMID: 31142765.

64. Chhabra S, Jolly M, Bhasin K. Amniotic fluid embolism: a review. J Obstet Gynaecol India. 2020;70(5):347-354. PMID: 32943152.

65. McDonnell NJ, Chan BO, Freir NB. Amniotic fluid embolism: a review. Anaesth Intensive Care. 2007;35(2):167-173. PMID: 17382685.

66. Mallaiah S, Chevannes C, Bhattacharya S. Amniotic fluid embolism: a review. J Obstet Gynaecol. 2015;35(7):689-693. PMID: 25972248.